Cullen/Frost Bankers stock price target raised to $147 by BofA

Cullen/Frost Bankers (CFR) reported stronger-than-expected Q1 EPS and raised its FY2025 guidance, leading BofA Securities to maintain a Buy rating and increase its price target to $147. While the regional bank has seen a 43.57% annual return and management anticipates 2026 will be a "payoff year" for significant investments, it trades at a premium valuation (14.1x FY26 EPS vs. peer median 10.4x) and has experienced expense growth outpacing revenue. The market's focus is now on whether these investments will translate into accelerated EPS growth and improved return on tangible common equity to justify current multiples, reflecting the mixed analyst sentiment, including a recent Underperform rating from Jefferies.

Analysis

Cullen/Frost Bankers (CFR) is at a pivotal point where its premium valuation is being tested against the execution of its long-term growth strategy. BofA Securities has reiterated its conviction with a Buy rating and a price target increase to $147, following a Q1 earnings per share of $2.30 that surpassed consensus estimates of $2.18 and a raised FY2025 guidance for net interest income and fee income growth to 5-7%. The bank's stock has delivered a strong 43.57% return over the past year, fueled by franchise investments. However, this momentum is shadowed by the fact that expense growth of 37% from FY2022-2025 has outpaced revenue growth of 33% over the same period. Consequently, CFR trades at a significant premium, with a forward P/E of 14.1x for FY2026 compared to a peer median of 10.4x. The investment thesis now hinges on management's ability to deliver on its 2026 "payoff year," where the market expects to see accelerated EPS growth and improved return metrics. The wide dispersion in analyst ratings, from Jefferies' Underperform initiation at $105 to BofA's bullish stance, underscores the debate over whether future earnings can justify the current multiple.

Key Decisions for Investors

• Investors should weigh the company's proven execution, as shown by the recent earnings beat and 33-year dividend history, against the significant risk posed by its premium valuation relative to peers.
• The key monitorable for the investment thesis is the trajectory of expense growth versus revenue growth; any failure to demonstrate positive operating leverage ahead of the targeted 2026 "payoff year" could trigger a valuation de-rating.
• Given the mixed analyst sentiment, from a Buy to an Underperform, investors may consider the stock a 'show-me' story, where positions should be contingent on management delivering tangible improvements in ROTCE and ROA in the coming quarters.